Publication: 3436

Publication: 3436

Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Blood Adv vol 5 (13) 2775-2787

Year:: 2021
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: collection

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No
Book Volume:: 10

Parents:: 607
Children:: None

Program:: OGC
Primary Committee:: Leukemia
Sec. Committees:

Pharmas:: Deltec Inc
Grants:: U10CA180821, U10CA180882, UG1CA233338, U24CA196171, P30CA033572, UG1CA233180, UG1CA233191, UG1CA233327, UG1CA233331, UG1CA233339, UG1CA189848, UG1CA189850, UG1CA189858

Corr. Author:
Authors:: Alison R. Walker Guido Marcucci Jun Yin William Blum Wendy Stock Jessica Kohlschmidt Krzysztof Mrózek Andrew J. Carroll Ann-Kathrin Eisfeld Eunice S. Wang Sawyer Jacobson Jonathan E. Kolitz Mohan Thakuri Grerk Sutamtewagul Ravi Vij Robert K. Stuart John C. Byrd Clara D. Bloomfield Richard M. Stone Richard A. Larson

Networks:: CA043, IA018, LAPS-AL002, LAPS-IL057, LAPS-MA036, LAPS-MO011, LAPS-NY158, LAPS-OH007, MUSC, NC031, NORTHWELL, OH070

Study: CALGB-10201
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords:: 20, 25, Clinical Trials and Observations